Articles

October 24, 2022 “Be the Link!” Learn from patients on World Amyloidosis Day No one knows this better than Jean-Christophe Fidalgo, President of the Amyloidosis Alliance, who has been living with hATTR amyloidosis for more than 20 years. Read More ›
September 27, 2022 Alnylam Named a Best Workplace for Women by Fortune Magazine Alnylam has been named a Fortune Best Workplace for Women for 2022 Read More ›
August 2, 2022 Alnylam Named #1 Best Workplace for Innovators by Fast Company Alnylam has been named the #1 Best Workplace for Innovators by Fast Company for 2022. Read More ›
July 13, 2022 Partnering with Nucleate to Support Young Biotech Entrepreneurs Alnylam is partnering with Nucleate to remove barriers for young biotech entrepreneurs... Read More ›
June 20, 2022 Challenging Ourselves to Help Refugees: Supporting Refugees to Become Work-Ready Alnylam has announced a three-year corporate partnership with Refugee Action, a United Kingdom (UK)-based charity dedicated to helping refugees... Read More ›
May 13, 2022 Hypertension: Charting A New Course to Address a Public Health Challenge Hypertension (high blood pressure) has seen limited medical innovation in recent history and remains a serious public health issue... Read More ›
May 9, 2022 Building a Collaborative Framework for Facilitating Patient Access to Innovative Therapies Alnylam worked with leading European economists and other healthcare experts to develop what we call the Value-Based Negotiation Framework (VBNF) to help... Read More ›
April 15, 2022 2021 Annual Report: CEO Yvonne Greenstreet Reflects on an Important Year in the RNAi Revol ... In conjunction with the publishing of Alnylam's 2021 Annual Report, Alnylam's CEO Yvonne Greenstreet reflects on the year that was... Read More ›
April 2, 2022 The Making of Two of Me: Living with Porphyria Cynthia Lowen, Emmy-nominated filmmaker, talks about the making of Two of Me: Living with Porphyria. Read More ›
March 16, 2022 Alnylam Publishes 2021 Corporate Responsibility Report We're committed to taking bold actions that improve the health of humanity. Our 2021 Corporate Responsibility Report provides details on our progress... Read More ›

You are now leaving Alnylam.com

The following content may not be associated with Alnylam Pharmaceuticals.

Links to all outside sites are provided as a reference for our visitors.

Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.

Proceed to Site